Abnova (Taiwan) Corporation (TPE:4133)
24.00
-0.20 (-0.83%)
Jan 22, 2026, 11:41 AM CST
Abnova (Taiwan) Revenue
Abnova (Taiwan) had revenue of 85.28M TWD in the quarter ending September 30, 2025, a decrease of -5.70%. This brings the company's revenue in the last twelve months to 355.40M, down -1.60% year-over-year. In the year 2024, Abnova (Taiwan) had annual revenue of 355.26M, down -7.01%.
Revenue (ttm)
355.40M
Revenue Growth
-1.60%
P/S Ratio
4.12
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 355.26M | -26.80M | -7.01% |
| Dec 31, 2023 | 382.05M | -29.70M | -7.21% |
| Dec 31, 2022 | 411.76M | -39.73M | -8.80% |
| Dec 31, 2021 | 451.49M | -4.96M | -1.09% |
| Dec 31, 2020 | 456.45M | 42.29M | 10.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chunghwa Chemical Synthesis & Biotech | 977.79M |
| Genomics BioSci & Tech. | 607.89M |
| Meribank Biotech | 486.52M |
| GenMont Biotech Incorporation | 391.48M |
| Taiwan Advance Bio-Pharmaceutical | 371.86M |
| GeneReach Biotechnology | 215.32M |
| NeoCore Technology | 190.10M |
| Lukas Biomedical | 180.32M |